Powered by

Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington's Disease (the "SIGNAL Trial") at Cambridge Healthtech Institute's 18th Annual PepTalk

Jan 17, 2019 - GlobeNewswire

ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth Evans, Ph.D., provided a podium presentation at the Cambridge Healthtech Institute's 18th Annual PepT...